Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $27.20 | Total: $136.00 |
| 1 | 10 | $23.04 | Total: $230.40 |
| 1 | 25 | $19.52 | Total: $488.00 |
| 1 | 50 | $16.64 | Total: $832.00 |
| 1 | 100 | $14.40 | Total: $1,440.00 |
Overview
CDK8-IN-13 is a CDK8 inhibitor (IC50: 51.9 nM) with potent, selective and oral activity. CDK8-IN-13 induces apoptosis and reduces the expression of p-STAT1 S727 and p-STAT5 S726. CDK8-IN-13 exhibits anti-tumour activity.
Chemical Properties
| Molecular Formula | C14H11N3O |
| Molecular Weight | 237.26 |
| CAS Numbers | 918523-75-8 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | C(N)(=O)C=1C=C(C=2C=C3C(=NC2)NC=C3)C=CC1 |
Storage and Handling
0C Short Term, -20C Long Term
References
Zhang XX, et al. Discovery of a novel oral type ? CDK8 inhibitor against acute myeloid leukemia. Eur J Med Chem. 2023 ; 251 115214.